vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $33.17 and traded as low as $31.55. vTv Therapeutics shares last traded at $31.95, with a volume of 52,700 shares traded.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on VTVT shares. Rodman & Renshaw initiated coverage on shares of vTv Therapeutics in a research note on Tuesday, June 30th. They set a "buy" rating and a $67.00 target price on the stock. HC Wainwright reduced their price target on shares of vTv Therapeutics from $45.00 to $42.00 and set a "buy" rating for the company in a research note on Thursday, August 6th. BTIG Research boosted their price objective on shares of vTv Therapeutics from $49.00 to $57.00 and gave the company a "buy" rating in a report on Thursday, July 16th. Zacks Research downgraded shares of vTv Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Friday, August 7th. Finally, Weiss Ratings cut shares of vTv Therapeutics from a "sell (d+)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Six investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $55.83.
Check Out Our Latest Stock Report on VTVT
vTv Therapeutics Trading Down 0.2%
The stock has a market cap of $125.85 million, a P/E ratio of -30.14 and a beta of 0.29. The company's 50 day moving average price is $33.17 and its two-hundred day moving average price is $34.59.
vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last announced its earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.08). On average, sell-side analysts anticipate that vTv Therapeutics Inc. will post -2.35 earnings per share for the current year.
Institutional Investors Weigh In On vTv Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. purchased a new position in vTv Therapeutics during the fourth quarter valued at $221,000. Geode Capital Management LLC increased its position in vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company's stock worth $1,128,000 after buying an additional 12,896 shares in the last quarter. Finally, 683 Capital Management LLC bought a new position in shares of vTv Therapeutics in the fourth quarter worth about $731,000. 17.51% of the stock is currently owned by hedge funds and other institutional investors.
vTv Therapeutics Company Profile
(
Get Free Report)
vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.
The company's lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer's disease.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider vTv Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and vTv Therapeutics wasn't on the list.
While vTv Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
